Genentech Earnings Win, But Drugs Miss (DNA)

Health and Healthcare

Published: January 14, 2008 4:18 pm

Last Updated: March 26, 2020 7:16 pm

Genentech (NYSE: DNA) just announced its earnings were $0.69 EPS on $2.96 billion for the last quarter, and First Call had estimates pegged at $0.67 EPS on revenues of $2.97 Billion. The company has also guided its fiscal 2008 Earnings Per Share in a range of $3.30 to $3.47 EPS versus $3.37 estimates from First Call.

We noted that Wall Street has focused on the individual drug disappointments here from drug to drug for too long, but today’s problem is one that is hard to overlook even if you are more of a big picture sort of investor. It isn’t that it didn’t have any significant outperformance. Genentech missed on Wall Street expectations on all four of its top four drugs.

The good news is that shares of Genentech are only down about 2% at $69.15 in after-hours trading, and $65.35 is the 52-week low from December. We noted that options traders were pricing in only a move of up to about $2.50 in either direction, and the $1.49 drop is well within that range.

We’ll have to see if any downgrades come in based on all top four drugs showing disappointment win over the calls of "unbelievable valuation" and "incredible valuation" calls from Wall Street analysts. Until then, this is just an unfinished biotech earnings and post-earnings story.

Jon C. Ogg
January 14, 2008

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.